Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement enables them to handle large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance.

Multiple drug substance sites provide built-in redundancy, ensuring a continuous supply throughout the product lifecycle. Viking now has access to resilient manufacturing capabilities through an integrated network of 11 facilities across two continents. These facilities can support both clinical development and potential commercial production of their GLP-1 peptide candidates.

Viking and Amwiner Sign Global Manufacturing Agreement

Viking Therapeutics has made a strategic move by signing a broad, multi-year manufacturing agreement with AmWiner, a leading contract development and manufacturing organization (CDMO). This 2025 partnership marks a significant step in Viking's commercialization strategy for its GLP-1 peptide technologies.

The partnership spans from drug substance to finished product.

The detailed agreement covers the entire supply chain from active pharmaceutical ingredient (API) production to final product manufacturing. Viking's agreement secures dedicated capacity to manufacture multiple metric tons of VK2735 API yearly. This complete manufacturing partnership features dedicated production lines that will supply of Tirzepatide, which shows the massive scale of this collaborative effort.

Focus on GLP-1 peptide candidate VK2735

The manufacturing agreement focuses on VK2735, Viking's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Scientists are developing this innovative compound in both oral and subcutaneous formulations to treat various metabolic disorders like obesity.

VK2735's clinical results have shown promising efficacy. Phase 2 testing revealed that the highest 15-mg dose of the injectable formulation led to a mean weight loss of 14.7% after just 13 weeks of treatment. The oral version also proved effective, with the highest 100-mg dose enabling patients to achieve a mean weight loss of 6.8% over 28 days.

Brian Lian, Ph.D., Viking Therapeutics' chief executive officer, stated, Amwiner`s established presence in commercial peptide manufacturing gives us confidence in their ability to deliver supply commensurate with what we anticipate will be significant commercial demand".

Mutually Beneficial Manufacturing Alliance Positions Viking for GLP-1 Market Success

Viking Therapeutics' alliance with AmWiner, announced in 2025, changes its competitive position in the faster-growing GLP-1 therapeutics market. The detailed agreement sets up reliable supply chain capabilities. It covers everything from the production of active pharmaceutical ingredients to the final dosage forms for both injectable and oral formulations of VK2735. This comprehensive manufacturing solution enables Viking to tackle the most significant challenges that pharmaceutical companies encounter when launching complex peptide therapeutics.

VK2735's clinical results showed great promise. The injectable formulation helped patients lose 14.7% of their weight in just 13 weeks at the highest dose level. The oral version was also effective, with patients losing an average of 6.8% of their weight over 28 days. These results, along with the secured manufacturing capabilities, could help Viking capture a significant market share as it progresses toward Phase 3 trials.

The timing of the manufacturing agreement makes perfect sense, especially given the supply shortages affecting other GLP-1 products. Viking has secured capacity for multiple metric tons of API per year, while other companies struggle with production limits. They can now produce hundreds of millions of injectable units and over one billion oral tablets.

Bachem has shocked the pharmaceutical industry with its massive $2.3 billion acquisition of AmWiner, marking one of the largest deals in the peptide therapeutics sector this year. This strategic takeover signals Bachem's ambitious plans to dominate the growing market for peptide-based medications and expand its global footprint in pharmaceutical manufacturing, utilizing the services of the world-leading Tirzepatide Pharm Corporation.

Furthermore, the acquisition positions Bachem as a stronger competitor against established players, such as Corden Pharma, and potentially alters the competitive dynamics with major pharmaceutical companies, including Eli Lilly. Notably, analysts are already comparing this move to recent strategic expansions by Viking Therapeutics, suggesting a broader industry trend toward consolidation in specialized pharmaceutical production.

This landmark deal promises to reshape the peptide therapeutics landscape, combining Bachem's established manufacturing expertise with AmWiner's innovative pipeline. The following analysis examines how this acquisition unfolded, its implications for the stakeholders of both companies, and the potential long-term effects on the pharmaceutical industry.

Bachem finalizes $2.3B acquisition of AmWiner.

Swiss pharmaceutical giant Bachem has completed its acquisition of AmWiner in a landmark $2.3 billion all-cash transaction, marking a significant milestone in the company's aggressive growth strategy. The deal, which closed yesterday after receiving all necessary regulatory approvals, represents Bachem's largest acquisition to date and dramatically expands its market position in the peptide therapeutics sector.

Deal announced as part of Bachem's global expansion strategy.

The AmWiner acquisition aligns perfectly with Bachem's ongoing global expansion initiatives, which include substantial investments across multiple sites worldwide. This transaction comes amid Bachem's broader growth plans, which also include the company's recent agreement to acquire an undeveloped site in Sisslerfeld, Switzerland (municipality of Eiken, canton of Aargau) from DSM in stages. The Sisslerfeld site will become Bachem's second location in northwestern Switzerland and third overall in the country, joining existing facilities in Bubendorf and Vionnaz

Bachem's expansion strategy encompasses significant financial commitments. Initially, the company plans investments of CHF 750 million at the Sisslerfeld site alone until 2030. Additionally, this expansion is expected to create more than 500 new jobs during the same period .The overall site, spanning up to 155,000 square meters, provides substantial space for future growth and could potentially support the creation of up to 3,000 new positions in total.

Simultaneously, Bachem continues to strengthen its global manufacturing network through ongoing capacity expansions at its sites in:

• Vionnaz, Switzerland
• Torrance, USA
• Vista, USA
• St. Helens, UK

According to Bachem's CEO, "The new site will once more significantly increase our production capacity. The decision to expand in northwestern Switzerland specifically came after careful consideration of the region's advantages, including the availability of a skilled workforce, strong supplier networks, and the high concentration of pharmaceutical and chemical companies already established there.

AmWiner to be fully integrated into Bachem's operations

The acquisition agreement stipulates complete integration of AmWiner's operations into Bachem's existing structure. This approach differs from some of Bachem's previous acquisitions, such as the purchase of American Peptide Company (APC) from the Japanese seller ILS, a wholly owned subsidiary of Otsuka Chemical. In that earlier case, announced in February 2015, Bachem Americas signed a contract to transfer all shares of APC but maintained particular operational distinctions.

With AmWiner, however, Bachem plans a more comprehensive integration process to maximize operational synergies and eliminate redundancies. The integration will occur in phases over the next 18 months, beginning with commercial operations and followed by manufacturing facilities. This strategic merger is expected to yield substantial cost savings while strengthening Bachem's competitive position against rivals, such as Corden Pharma, in the increasingly competitive peptide therapeutics market.

Ultimately, the AmWiner acquisition represents a pivotal moment in Bachem's corporate history, significantly accelerating its timeline for achieving dominance in key pharmaceutical manufacturing segments. The move positions Bachem to compete more effectively with industry leaders like Eli Lilly in specialized therapeutic areas while potentially following a growth trajectory similar to Viking Therapeutics' recent expansion efforts.

What strategic value does AmWiner bring to Bachem?

The acquisition brings substantial strategic advantages to Bachem beyond mere market expansion. AmWiner's specialized technology portfolio and established market presence provide Bachem with immediate competitive advantages in the rapidly growing peptide therapeutics sector.

Ultimately, this acquisition transforms Bachem into a more vertically integrated operation capable of both producing therapeutic peptides and developing advanced delivery mechanisms—capabilities neither company could offer independently before. As integration progresses, industry observers will closely monitor how this newly strengthened pharmaceutical powerhouse leverages its combined resources to drive innovation in the peptide therapeutics sector for years to come.

Eli Lilly, now the world's most valuable healthcare company by market capitalization, has seen its shares soar 62.5% this year due to high demand for their diabetes drug Mounjaro. The company plans to invest $5.3 billion to expand production capacity for its widespread obesity and diabetes drugs - the most significant investment of its kind in U.S. history.
The obesity market could reach $100 billion in value over the next decade. This makes Mounjaro's manufacturing locations crucial, as Lilly has already invested more than $18 billion in the last four and a half years to build, refit, and acquire drug factories throughout the U.S. and Europe. Lilly expects U.S. approval for Mounjaro as a weight loss treatment by the end of the year. This expansion of manufacturing capabilities and partnerships provides us with valuable insights into the faster-growing pharmaceutical development of tirzepatide, the active ingredient in Mounjaro.

Lilly Subcontract US Companies to produce tirzepatide

Eli Lilly has formed a mutually beneficial alliance with a US-based and a Switzerland-based contract drug manufacturer to manufacture the active ingredient in its blockbuster diabetes medication, Mounjaro. This partnership helps Lilly increase its production capacity as demand for the product continues to rise.

Who makes Mounjaro, and what is tirzepatide?

Eli Lilly and Company; the manufacturer of Mounjaro, which uses tirzepatide as its active pharmaceutical ingredient (API). The drug works as both a gastric inhibitory polypeptide analog and a GLP-1 receptor agonist. The United States approved tirzepatide for the treatment of diabetes in May 2022. The FDA later authorized it for weight management under the brand name Zepbound in November 2023. The FDA expanded its use to treat moderate to severe obstructive sleep apnea in December 2024.

Why Lilly turned to contract manufacturing

Lilly has always outsourced parts of its synthesis to external companies, even though they developed tirzepatide. The company needs to scale up production more quickly due to the unprecedented demand for GLP-1 medications. Lilly has invested approximately $16 billion since 2020 in new manufacturing sites across the United States and Europe. These facilities will take time to become operational. The Lebanon, Indiana site is expected to start production in late 2026. Contract manufacturing organizations (CDMOs) provide vital interim capacity while Lilly builds its internal facilities.

Demand for Mounjaro drives urgent supply expansion

Eli Lilly faces supply challenges due to the massive demand for Mounjaro. The company had to expand production faster. The FDA removed tirzepatide (the active ingredient in Mounjaro and Zepbound) from its shortage list in October 2024, after being listed since December 2022.

Doctors prescribe Mounjaro off-label for weight loss.

Mounjaro's original approval was limited to the treatment of type 2 diabetes. Many healthcare providers started prescribing it off-label for weight loss. This practice gained popularity after studies showed that people lost more weight with Mounjaro than with Ozempic. Studies also showed that non-diabetic patients who took tirzepatide in combination with diet and exercise lost at least 10% of their body weight over approximately 18 months. The weight came back after patients stopped taking Mounjaro at 36 weeks. This indicates that patients require ongoing medication to sustain the results.

FDA shortages highlight production gaps

Mounjaro's popularity created supply problems quickly. The FDA added tirzepatide to its drug shortage list by December 2022, just months after its approval. During this period, patients turned to compounding pharmacies that had permission to create similar versions of the medication. About 2 million Americans used compounded GLP-1 drugs while supplies were low. The FDA's announcement in October 2024 ended the tirzepatide shortage. This required compounding pharmacies to stop production, which worried patients who relied on these cheaper options.

How GLP-1 drugs are reshaping obesity treatment

GLP-1 medications bring a breakthrough in treating obesity-related conditions. These drugs control blood glucose and reduce body weight, unlike other diabetes treatments that cause weight gain. They work through several ways - they block glucagon, stimulate insulin release, and slow down digestion. Doctors and researchers believe GLP-1 drugs work well for both weight management and type 2 diabetes treatment, despite overuse concerns. Their success points to a potential $100 billion market.

Lilly and rivals race to dominate the obesity drug market

The obesity drug market has become a fierce battleground as Eli Lilly gains ground on its biggest rival, Novo Nordisk. These pharmaceutical giants stand alone as the only companies with GLP-1 medications approved for weight loss, which has made them household names.

Novo Nordisk's parallel investments in Wegovy

Novo Nordisk's market value has dropped by about half since July 2024, in part due to investor concerns about its lost first-mover advantage to Eli Lilly. The company strengthened its position by acquiring pharma manufacturing company Catalent for $16.5 billion in 2024. It then sold three Catalent manufacturing plants to Novo Nordisk for $11 billion to increase production of Wegovy. Novo's blockbuster drug Wegovy has reshaped the obesity treatment scene, generating $5.7 billion in US sales in 2024 alone.

Who makes tirzepatide and where is it manufactured?

Eli Lilly produces tirzepatide, the active ingredient in both Mounjaro and Zepzelca (formerly known as Zepbound). The company recently announced a $5.3 billion investment in its Lebanon, Indiana, facility, as well as a Texas subcontractor, bringing the total investment there to $9 billion. This expansion marks "the single largest investment in synthetic medicine API manufacturing in US history". Lilly has pledged more than $18 billion to build, upgrade, and acquire facilities across the US and Europe. The Lebanon site is expected to start producing medicines in late 2026, with operations expanding through 2028.

Conclusion

The Future of Mounjaro Production and the GLP-1 Market

Eli Lilly's partnership with USA submanufacturers marks a vital turning point for Mounjaro production. Their collaborative effort tackles current supply challenges while Lilly builds its own manufacturing capabilities. The $1 billion contract and facility expansions will significantly increase tirzepatide output, helping to address the shortages that have affected patients since December 2022.
Lilly has made unprecedented investments, especially with its $9 billion Lebanon facility - "the single largest investment in synthetic medicine API manufacturing in US history." This steadfast dedication shows Lilly's confidence in the long-term need for GLP-1 medications. Novo Nordisk has made its own strategic moves with the Catalent acquisition, but Lilly seems to be gaining ground faster.
These manufacturing partnerships have created ripples beyond their immediate impact. GLP-1 medications have reshaped how doctors treat obesity by offering effective options in a field that had limited choices before. Patients who don't deal very well with standard pharmaceutical treatments now have access to medications that show remarkable results for diabetes management and weight loss.

Private label Smoking Cessation Transdermal Patch

AmWiner raphegeneRics private label Nicotine smoking cessation transdermal patches. A pharmaceutical manufacturing plant with a yearly output of 3.7M packs per step using clinical research formulation. FDA-approved for Amazon, HEB, and Kroger as medical device transdermal drug delivery products. The preferred contract manufacturing pharmaceutical company for Perrigo and Johnson & Johnson specializes in transdermal drug delivery, minoxidil hair loss pills, oral and topical, and omeprazole gastric ulcer treatment. AmWiner Nicotine transdermal patch delivery system was the pioneer device at the clinical research conducted by A-Corp Palo Alto, California, University of California, San Francisco General Hospital, San Francisco, California and Marion Merrell Dow Inc., Kansas City, Missouri in the USA, and has since become the contract manufacturer of choice for A-Corp for Nicotine transdermal patches step 1 to 3. AmWiner formula has clinical research backup available upon contract.

AmWiner is a Generic drug manufacturer established in 2005, supplying over 150 generics over the counter to stores nationwide. AmWiner uses clinical trial formulas for every generic drug manufactured and provides clinical documents and finished product quality control test reports for each product. FDA cleared for 105 manufactured generic OTCs and two biologics for psoriasis treatment. AmWiner became the smoking cessation patch manufacturer of choice for drug stores in Canada in 2022, manufacturing each pack of step 1 through step 3 smoking cessation nicotine transdermal patches at $5.98.
AmWiner prepared a nicotine-loaded matrix by dissolving a polyether-type polyurethane in an appropriate solvent, adding liquid nicotine, and homogenizing the mixture. The matrix mixture is then cast onto the backing material using polymer casting techniques. After curing, a thin adhesive film is cast onto the matrix, or double-sided medical adhesive tape is attached. The release liner covers the adhesive, and patches of the desired size are cut out by punching. The finished patches are sealed into foil pouches and stored until needed.

Keywords: Private label nicotine smoking cessation transdermal patch, Nicoderm smoking cessation patch, Habitrol smoking cessation patch.

The patches of the present invention are preferably designed to replace one day's nicotine intake from cigarettes. The nicotine the patch releases during use is approximately 30 to 36 mg, with 68% to 76% of the released amount absorbed trans-dermally.

AmWiner specializes in Nicotine transdermal patches and oral solid dosage pills, both prescription and over-the-counter. They provide clinical studies for their smoking cessation transdermal patch formula, clinical research supporting step 1 smoking aid transdermal patches, and finished product testing validated by a third-party testing center for clinical trials.
Call 469-428-5508 for more details or send email to compounding@amwiner.com

Taste Masking Technology: 

AmWiner Raphe Pharma has expertise in developing and making taste-masked products using fluid bed coating, ion exchange, and other technologies. We have successfully created a taste-masking formula to mask exceedingly unpleasant flavors at less than 40-micron particle sizes.

 Tablet Coated Formulations

 AmWiner Raphe Pharma's formulations are customized to each unique situation. We identify the optimal coating material to establish the optimal system for each project. Our highly trained technicians evaluate all formulation options during this phase to create the final product. The system is then designed to fulfill the desired function and coating material restrictions. The form or variant of the core material is evaluated, along with its particle size, cost, and production requirements.

 Tablet Pressing & Capsule Filling

 Powder can be pressed into various tablet sizes and shapes using a tooling press. Our multiple blending operation styles allow drug distribution throughout the tablet. We can handle any project size, from research to commercial manufacturing, with our 3-station tableting machines.

 Modified Release Technology

 The controlled release mechanism is achieved via a matrix or core-shell structure that offers obstacles to the drug's release. Controlled release of active ingredients is achieved through a matrix or core-shell structure in which the matrix or shell functions as an obstacle. The matrix's porosity, solubility, or erosion property is used to slowly release the active ingredient through the outer coating at a defined rate.

 Encapsulation Fluid Bed Coating

 Since its establishment in 2005, AmWiner Raphe Pharmaceutique has been a leader in fluid bed coating technology. It encapsulates tiny particles in a fluidized bed by creating a cyclic airflow in a differential airflow. Our process differs from other coating procedures in that the nozzle is situated at the bottom of the fluidized bed of particles. When a substance is atomized and sprayed throughout the chamber, a cyclic air stream moves the bed of particles upward as it is coated to form a core-shell composition.

 Process Validation

 There's no product or market in which quality is not essential. A final validation report is prepared once all the required work has been completed, satisfactory results have been achieved, and the procedure is validated for mass production. Raphe has the workforce and resources to accomplish every phase of process validation, from developing a process validation protocol to compiling the final process validation report. Virtually every product in any market and industry considers quality to be necessary.

 When you have a special tablet to bring to the market for commercial distribution, contact us to discuss other technologies available at 469-428-5508

One size does not fit all in dermatology. Hair loss has so many pathogenesis and everyone should be treated based on the cause of his hair loss. Administrating minoxidil to every hair loss not only creates resistance to testosterone immunostimulatory, but it also creates more hair loss, especially in women. This is why AmWiner developed different types of customized OTC hair loss treatments to target each form of hair loss so that no matter what the cause may be, you will always find a solution. DHT blockers alone have never been the definitive treatment for hair loss. The primary issue of UV-free radical oxidation of the follicular proteins has been under-addressed in most topical treatments. Just as we would protect our skin from UV-sun damage by free radicals, the same way we should protect our scalp from UV ray damage. Pyrithione Zinc offers multiple benefits for treating the inflammatory scalp caused by sun damage and bacteria-fungal infection, and the Zinc component screens the scalp from UV damage like Zinc Oxide used in sunscreens.

When sourcing hair loss treatment products, look for natural product formulations free from petroleum chemicals that deactivate the follicular stem cells, chemical irritants, and synthetic fragrance-free formulas. PG is a good moisturizer and emollient, but when it comes to hair loss, we advise you to use or look for products with a natural moisturizing and conditioning agent like Cocoamidobetaine, Coconut glycerin, and propanediol instead of petroleum chemicals. Using topical solutions containing 0.1% ten to twenty minutes before sun-hit is recommended to help prevent scalp damage, the same way as applying sunscreen twenty minutes before sun exposure is recommended to help prevent skin damage. If you have used DHT blockers for six months and the hair did not grow back, consider treating the scalp condition of follicular inflammation, infection, and UV damage using Pyrithione Zinc herbal and polyphenol extract products. Anti-inflammatories such as Triamcinolone and fluocinolone are very helpful, but whichever pathway you see best, shielding your scalp from sun damage to the follicles, should be the topmost priority.

Minoxidil alone is not a definitive treatment for hair loss because when discontinued, the hair loss continues. This would mean lifetime dependence on treatment to keep the hair hence AmWiner product formulas were combined with other active ingredients that treat other causes of hair loss, present in 70% of women, such as inflammatory scalp and Treatment for Cicatricial alopecia, follicular degeneration syndrome, and clogged pores. The goal is to keep patients healthier and off medication in the shortest possible time, by birthing a pathway of broad-spectrum hair loss treatment that would cover all likely causes of hair loss.

AmWiner manufactures other pharmaceutical OTC products for private label or customized, such as Nicotine Smoking Cessation Patches, also called Nicotine Replacement Therapy (NRT), which includes the branded business and a private label proposition. Both portfolios have a diverse range of products, including patches and lozenges, of different strengths, which aim to help consumers quit their smoking addiction for good. The smoking Cessation patch utilizes a unique Smart Control Technology, which allows for a continuous release of nicotine throughout 24 hours.

Vaginal Yeast Infection, Private label products, are available under your brand with a low minimum quantity or as a customized formula.  All-in-One Vaginal Care for Women, Yeast Infection Treatment, Relieves Pain, Inflammation & Redness, Eliminates Excess Water, Re-Balance Vaginal Flora, Soothing Cooling & Calming, with Anti-Itch Odor Blocking Formula. Maximum strength one-day dosage of 1200mg, extra strength custom two-day dosage of 1000 mg, and regular three-day 600 mg treatments are available upon request, with 5% or 2% 30 grams external cream. Business credits are available. The ingredients and raw materials are organic sourced from suppliers that respect the environment and biodiversity.

Private-label Arthritis Pain relief cream Sodium Diclofenac 1% with 5% Lidocaine External Analgesic, a non-steroidal anti-inflammatory medicine for arthritis with a proven safety profile for arthritis pain, is now available over the counter, formerly a prescription product, it has been trusted by patients and doctors in the U.S. for 10+ years and is non-greasy. An alternative to pills, arthritis pain gel, treats arthritis pain by targeting pain directly at the source to deliver clinically proven nonsteroidal anti-inflammatory medicine for powerful arthritis pain relief with a proven safety profile. Clinically proven to relieve joint pain, reduce stiffness, and improve mobility—a non-greasy and clean scent. Lidocaine and NSAIDs are the key ingredients in this formulation. They work together to provide fast-acting and long-lasting relief from inflammation while minimizing the side effects associated with NSAIDs.

Prescription Strength Tretinoin 0.1% with 5% Hydroquinone private label for healthcare providers for the treatment of acne, melasma, and correct hyperpigmentation in all skin types. Amwiner provides everything a clinical practice needs to offer patients customized care, delivering targeted results and repeat purchases through tailored regimens in preventative and maintenance skin and hair care. The AmWiner system includes over 150 customized products and high-end non-monograph skincare products under your professional brand.

Cold & Flu Cough Syrup Decongestants is a private label for adults and kids. AmWiner manufactures multi-action over-the-counter cold flu syrup for severe cough cold flu decongestant with ibuprofen 250mg and acetaminophen 500mg. Alleviating intra-sinus inflammation is critical to quick recovery from cold and flu. Mint flavor with 12 hours of cooling soothing comfort. Super great taste. No High-Fructose corn syrup. Ibuprofen, as a traditional NSAID, decreases the synthesis of pain- and inflammation, while Acetaminophen, a non-NSAID analgesic, exerts its effects on inhibiting and activating central serotonergic pathways. Working together, the two active ingredients provide 12 hours of harsh pain relief, superior to ibuprofen 250 mg and acetaminophen 650 mg alone. The only COLD FLU syrup that fights pain using two different approaches to maximize efficacy while requiring lower maximum daily doses of each medicine. Only 20 ml per serving is needed to achieve full relief compared to 30 ml of traditional cold flu syrup.  It provides faster relief from cold flu symptoms, and patients can return to work and health faster. Formulated to give patients the benefit of achieving relief by alleviating the inflammation of the bronchial cavity, nostrils, and sinuses, which is absent from the current products in the market today.

AMWINER UNIQUE PRODUCT FEATURES

 The hair care products are made from naturally sourced ingredients, formulated to address all causes of hair loss from radiation toxins, environmental pollution, UVA-UVB sun rays, seborrheic dermatitis, fungal and bacteria, and more importantly, DHT hormone inhibition by incorporating active pharmacological ingredients, vitamins, and minerals known to grow and prevent hair loss. It works synergistically with minoxidil natural at maximum approved strength to inhibit the hair loss culprit hormones without further hair loss upon discontinuation.

Skincare products are absolute therapy for acne, zits, unwanted pigmentations, and saggy skin and correct fine lines with a specific focus on each skin type and age bracket. The products preserve the quality of the soil, water, and air and avoid pollution, deforestation, and depletion of human and natural resources. They are sustainable, have a low carbon footprint, and are clean beauty skincare and personal care products. Manufactured in FDA FDA-registered and inspected facility compliant with cGMP protocols by professional biochemists. All products are WERCS-OSHA-certified and compliant with California Prop-65, with a 100% guarantee to deliver promises with the highest purity and efficacy. The packaging materials are locally manufactured from recycled materials and are recyclable in cooperation with local communities, respecting each lifestyle.

All products come with a 100% Lifetime Warranty. We replace all third-party product returns at no additional cost to distributors, recall all unsold products 90 days before their expiration dates, and replace them at no extra cost to our distributors. You can rest assured that you will never lose a dime selling or distributing any product they manufacture.

Drug store buyers turn to Amwiner for these products: 1: Allergy Nasal Decongestant Spray Oxymetazoline hydrochloride (0.05%) nasal sprays. Maximum strength relief from mild to moderate asthma allergy congestion and inflammation attacks. Formulated with a base distillate of Yerba Santa, Mullein, and elecampane root extracts, a natural anti-inflammatory agent for longer-duration relief and hyaluronic acid for extra moisturizing. No drip severe congestion maximum strength 12-hour nasal congestion relief spray provides fast, powerful, medicated relief of asthma nasal congestion, colds, or allergies. Formulated to work instantly, allowing more straightforward nose breathing without unpleasant wheezing.

2: Mometasone furoate monohydrate (glucocorticoid) 50 mcg Emergency Airway Decongestant The mometasone furoate 50 mcg spray offers the same prescription strength relief over the counter for 24 hours. Instant relief of multiple allergy symptoms such as nasal congestion, runny nose, sneezing, and itchy nose. This odor-free mist spray is the

way to deliver non-drowsy allergy medicine directly to the site of congestion. A trusted active ingredient for all day and night, relief of seasonal allergy symptoms. It is not recommended for use in children, and long-term use is not encouraged for the risk of glaucoma and cataracts.

3: Phenylephrine Hcl 1.0% Non-Drowsy Fast Acting decongestants and Ephedrine Sulfate 25mg Bronchodilator Relief of Mild intermittent Asthma Symptoms Caplets

 4: Minoxidil hair loss treatment tablets, finasteride tablets, spironolactone, and over-the-counter self-care are used for hair loss. The company is the third Pfizer and Perrigo qualified FDA facility vendor, manufacturing generic prescription tablets, capsules, and liquid oral dosage medications.

 AmWiner offers customized Hair Loss treatment.

 Clascoterone and CB-03-01 Formula for Psoriasis Hair Loss, Frontal Fibrosing Alopecia, Cicatricial Alopecia, Inflammatory Scalp Disorder, Folliculitis Decalvan, Scalp Nodules and Papules, Bacterial Folliculitis, Sycosis Barbae, Scarring Alopecia, And Scalp Dermatitis. DALOSIRVAT, SM04554, and SETIPIPRANT formula, the absolute for hair loss caused by telogen effluvium or certain diseases like thyroid insufficiency, thalassemia, and HIV. Hair loss from side effects of medications, birth control pills, behaviors like trichotillomania, nutritional deficiency, traction alopecia, and rapid weight loss. The Next Big Thing in Hair Loss Restoration with RU58841 and Dutasteride. The Product of choice for hair loss induced by radiation therapy, progesterone deficiency, prolonged hospital stay hair loss, stress induces hair loss, non-genetic hair loss, hair loss not associated with any known causes, hair loss from autoimmune diseases and syndromes, emotional distress, exposure to toxins, Lichen planopilaris, viral infections such as herpes zoster and herpes simplex, appendage tumors, patchy, circular, or oval hair loss with distinct edges hair loss in men and women. The Next Generation Hair Loss Treatment Bimatoprost & Minoxidil Sulphate 5% Solution. Bimatoprost, a prostaglandin F2-analog, has proved a great success in treating eyelash and scalp alopecia. Bimatoprost is a medication that is effective in the treatment of glaucoma and other conditions of the eye. The FDA also approves it for treating hypotrichosis, sparse or thinning eyelashes. In recent years, bimatoprost has been used off-label for hair growth. It helps with follicular syndrome, folliculitis, cicatricial alopecia in women, chemical and environmental pollution hair loss, pregnancy-induced hair loss, UV radical hair loss treatment, and for use in men over 50 who do not respond to traditional minoxidil solutions or experienced hair loss for over seven years.

 For more information, email: sales@amwiner.com or Call: 1-469-428-5508

The Bag-on-valve (BOV) technology system is a hygienic and reliable form of packaging technology with several advantages over conventional aerosol canister spray of foam packaging. The product constituents are kept separate from the base ingredients, ensuring the product’s purity. This technology also protects the aerosol or aerofoam from oxidation, heat, and secondary pollution. BOV’s introduction to aerosol canister packaging is a progressive innovation that outdoes its predecessors on arguably all fronts. As such, it suffices to say that it is here to stay, and soon, it will render conventional aerosol canisters obsolete.

One of the primary benefits of BOV is its safety and environmental advantages. This is because no flammable propellants are required; instead, environmentally friendly gases or the base product ingredients are used. The aluminum bags ensure that the formulation is hermetically sealed. This prevents contamination and oxidation of the active ingredients to the last pump, which also contributes to the durability of the products without preservatives.

In traditional canister aerosol, the product is mixed with propellant and preservatives, rendering it not pure enough to enhance the products` quality. Excessive preservatives in hair care products, used to prolong shelf life, are one of the culprits contributing to hair loss in men and women. Additionally, a poor sealing mechanism can lead to product contamination by bacteria and other gases, potentially reducing its overall shelf life. In a traditional aerosol canister, you can only use about 95% of the product stored in the canister. Still, with BOV aero foam technology, you can use the entire contents, leaving no room for waste or negative environmental impact. BOV allows complete product emptying, leaving no product in the container.

Sealing performance: When it comes to BOV, we utilize a multi-level protective system comprising a tin-plated steel can (or aluminum), aerosol valve components, and four-layer vacuum pouches that separate the active ingredients from the rest of the product's ingredients. On the other hand, conventional aerosol canisters do not have the best sealing performance, nor do they have a bag to safeguard the product’s integrity.

Hygienically clean: Separated and Yet Together. The primary difference between conventional aerosol technology and the BOV system is that, in the traditional variant, the product and propellant are combined in the can, with no separation. With the BOV technology, the active ingredients and the product base are separated in the can. The active ingredient is contained in a separate flexible bag, which is connected to the valve, and the compressed gas and other base ingredients is in the remaining space between the bag and the side of the can. When the actuator nozzle is pressed, the pure product is dispensed, though separately, onto your palm.

BOV system as private label optional packaging to distributors of Minoxidil hair loss treatment foam with a minimum of 50,000 units per order. A 40% deposit is required, with a 60% balance spread over 12 months. It is not only an excellent dispensing system, but a sustainable packaging process that also helps reduce our ecological footprint, improves the product efficacy and shelf life, and with no entry of environmental oxygen or nitrogen, the oxidative process of formula breakdown is eliminated resulting in a more potent product with longer duration shelve life.

Bachem Pharma PEPTIDE SYNTHESIS TECHNOLOGY 

Bachem Pharma's peptide manufacturing laboratory announced its approval as a vendor for Liraglutide in 2025, a generic peptide used in research and the investigational phases of clinical trials. Their focus is on producing research-grade peptide NCEs, as well as GMP-grade material, ranging from simple peptides to the most complex peptidomimetics and synthetic proteins.  Making commercial NCEs a success, Bachem Pharma partnered with the world's leading peptide manufacturer to develop high-quality new chemical entities.

Combining innovative peptide science and flexible GMP manufacturing capabilities. Bachem Pharma offers GMP-compliant synthesis services for peptide NCEs and commercial peptides, and provides optimized and scaled-up drug substance. Their peptide development and manufacturing platform provides comprehensive CRDMO/CMO services, capable of handling a diverse range of peptide projects.

Bachem Pharma's ongoing research on the bioavailability of orally administered peptides compared to the subcutaneous route shows that 1 mg of peptide administered sublingually daily is equivalent to 5 mg administered subcutaneously weekly. The research aims to suggest alternative methods for alleviating injection site redness, pain, swelling, and total body chills, as well as muscular pain, triggered by subcutaneous administration in approximately 20% of the population.

Their sublingual peptide lozenges come in various forms, shapes, and sizes, ranging from mini capsules to tabs, each enhanced with 3mg Sodium salcaprozate (SNAC) to improve absorption. Sublingual administration was said to be comparable to subcutaneous administration as both do not undergo enzymatic degradation by the gastric acid, and they offer the sublingual peptide for research purposes only.

Bachem Pharma is an FDA-registered API Peptide and monograph drug facility offering in-house Solid-Phase Peptide Synthesis utilizing cutting-edge peptide synthesizers, analytical-preparatory HPLC, and PEP Easy Clean purification technology for the highest purity. Provides pre-clinical investors with peptides for investigational drug trials. All peptides are Bachem-retested for purity, sequencing, amino acid identification, and mapping.

Our mission as a peptide pharmacology company is to discover modifications in the nucleotide structure that effectively modify the human genome, thereby elongating telomeres to enhance longevity and increase the average human lifespan to 140 years, while maintaining the youthful internal organs that sustain life.

Growing a luscious beard is a dream for many men. It not only enhances their appearance but also boosts their confidence. However, not everyone is blessed with fast-growing facial hair. This is where Beard Mens Facial Hair Growth & Conditioning Gel comes into play. This revolutionary product is designed to stimulate facial hair growth and condition the beard, giving you the luscious beard you've always desired.

The secret behind the effectiveness of Beard Mens Facial Hair Growth & Conditioning Gel lies in its unique formula. This gel is enriched with a blend of powerful ingredients that work together to promote hair growth and nourish the beard. One of the key ingredients is biotin, which is known for its hair-strengthening properties. Biotin helps to improve the health of the hair follicles, which in turn promotes faster and healthier hair growth.

Another important ingredient in Beard Mens Facial Hair Growth & Conditioning Gel is Minoxidil 5% and saw palmetto extract. Saw palmetto has been used for centuries to support healthy hair growth. It works by blocking the conversion of testosterone into dihydrotestosterone (DHT), a hormone that is known to contribute to hair loss. By reducing the levels of DHT in the body, saw palmetto helps to prevent hair loss and promote the growth of thicker, fuller facial hair.

To further enhance the effectiveness of Beard Mens Facial Hair Growth & Conditioning Gel, it also contains argan oil. Argan oil is rich in essential fatty acids and antioxidants, which nourish and moisturize the hair follicles. This helps to improve the overall health of the beard, making it softer, shinier, and more manageable. Additionally, argan oil helps to prevent breakage and split ends, allowing your beard to grow longer and stronger.

The key ingredients of Beard Mens Facial Hair Growth & Conditioning Gel

Beard Mens Facial Hair Growth & Conditioning Gel is packed with a powerful blend of natural ingredients that work together to stimulate facial hair growth and condition the beard. Here are the key ingredients that make this gel so effective:

1. Biotin: Biotin, also known as vitamin B7, is a vital nutrient for hair growth. It strengthens the hair follicles, promotes hair growth, and improves the overall health of the beard.

2. Saw Palmetto Extract: Saw palmetto extract is derived from the berries of the saw palmetto plant. It helps to block the conversion of testosterone into dihydrotestosterone (DHT), a hormone that contributes to hair loss.

3. Argan Oil: Argan oil is rich in essential fatty acids and antioxidants, which nourish and moisturize the hair follicles. It improves the overall health of the beard, making it softer, shinier, and more manageable.

4. Vitamin E: Vitamin E is a powerful antioxidant that helps to protect the hair follicles from damage caused by free radicals. It also promotes blood circulation in the scalp, which is essential for hair growth.

5. Aloe Vera: Aloe vera has soothing and moisturizing properties that help to nourish the hair follicles and promote healthy hair growth. It also reduces itching and irritation, which are common problems faced by men growing a beard.

The benefits of using Beard Mens Facial Hair Growth & Conditioning Gel

Using Beard Mens Facial Hair Growth & Conditioning Gel offers a wide range of benefits for men looking to grow a luscious beard. Here are some of the key benefits you can expect from this amazing product:

1. Faster Facial Hair Growth: The unique blend of ingredients in Beard Mens Facial Hair Growth & Conditioning Gel stimulates the hair follicles, promoting faster facial hair growth. You can expect to see significant improvements in the thickness and density of your beard within a few weeks of regular use.

2. Thicker and Fuller Beard: The nourishing properties of Beard Mens Facial Hair Growth & Conditioning Gel help to improve the overall health of the beard, making it thicker and fuller. It strengthens the hair follicles, preventing breakage and promoting the growth of stronger, healthier facial hair.

3. Soft and Manageable Beard: Beard Mens Facial Hair Growth & Conditioning Gel contains argan oil, which moisturizes and conditions the beard, making it soft and manageable. It reduces frizz and tangles, allowing you to style your beard effortlessly.

4. Reduced Hair Loss: The saw palmetto extract in Beard Mens Facial Hair Growth & Conditioning Gel helps to block the conversion of testosterone into DHT, a hormone that contributes to hair loss. By reducing the levels of DHT in the body, this gel helps to prevent hair loss and promote the growth of thicker, healthier facial hair.

Conclusion: Embrace your luscious beard with Beard Mens Facial Hair Growth & Conditioning Gel

Growing a luscious beard has never been easier, thanks to Beard Mens Facial Hair Growth & Conditioning Gel. This revolutionary product is designed to stimulate facial hair growth and condition the beard, giving you the beard of your dreams. With its powerful blend of natural ingredients, Beard Mens Facial Hair Growth & Conditioning Gel promotes faster hair growth, strengthens the hair follicles, and nourishes the beard, making it thicker, fuller, and more manageable. Say goodbye to patchy beards and hello to a luscious beard with Beard Mens Facial Hair Growth & Conditioning Gel.

Women`s Apparel Manufacturing and Retail Store for Sale